Free Trial

Insulet (PODD) Competitors

Insulet logo
$268.32 +2.93 (+1.10%)
Closing price 03/21/2025 04:00 PM Eastern
Extended Trading
$268.33 +0.01 (+0.01%)
As of 03/21/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PODD vs. BDX, EW, IDXX, RMD, DXCM, STE, BAX, HOLX, GMED, and MASI

Should you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.

Insulet vs.

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership.

In the previous week, Becton, Dickinson and Company and Becton, Dickinson and Company both had 34 articles in the media. Becton, Dickinson and Company's average media sentiment score of 1.29 beat Insulet's score of 0.87 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
25 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insulet
16 Very Positive mention(s)
6 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Insulet received 134 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 66.40% of users gave Insulet an outperform vote while only 62.41% of users gave Becton, Dickinson and Company an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson and CompanyOutperform Votes
601
62.41%
Underperform Votes
362
37.59%
InsuletOutperform Votes
735
66.40%
Underperform Votes
372
33.60%

Becton, Dickinson and Company has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$20.64B3.21$1.71B$6.0238.31
Insulet$2.07B9.10$206.30M$5.7946.34

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.5% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Insulet has a net margin of 20.19% compared to Becton, Dickinson and Company's net margin of 8.47%. Insulet's return on equity of 24.46% beat Becton, Dickinson and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company8.47% 15.74% 7.29%
Insulet 20.19%24.46%8.33%

Becton, Dickinson and Company presently has a consensus price target of $278.29, indicating a potential upside of 20.66%. Insulet has a consensus price target of $292.06, indicating a potential upside of 8.85%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, equities research analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Insulet
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.82

Summary

Insulet beats Becton, Dickinson and Company on 10 of the 17 factors compared between the two stocks.

Remove Ads
Get Insulet News Delivered to You Automatically

Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PODD vs. The Competition

MetricInsuletSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$18.84B$4.44B$5.70B$8.12B
Dividend YieldN/A29.37%4.41%4.08%
P/E Ratio46.3429.0824.1518.94
Price / Sales9.1050.58394.5890.47
Price / Cash75.9651.0838.1634.64
Price / Book25.586.237.104.43
Net Income$206.30M$67.64M$3.19B$247.05M
7 Day Performance5.04%9.59%1.91%1.96%
1 Month Performance-5.12%-2.97%3.55%-6.07%
1 Year Performance63.30%22.51%14.43%3.77%

Insulet Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PODD
Insulet
3.9643 of 5 stars
$268.32
+1.1%
$292.06
+8.8%
+61.0%$18.84B$2.07B46.343,000
BDX
Becton, Dickinson and Company
4.8317 of 5 stars
$227.84
+0.8%
$278.29
+22.1%
-4.5%$65.42B$20.64B37.8574,000Insider Trade
Positive News
EW
Edwards Lifesciences
4.8222 of 5 stars
$70.67
+2.0%
$79.95
+13.1%
-25.6%$41.55B$5.44B10.1417,300Positive News
IDXX
IDEXX Laboratories
4.2999 of 5 stars
$422.36
+1.7%
$533.75
+26.4%
-20.9%$34.35B$3.90B39.5810,800News Coverage
Positive News
RMD
ResMed
4.7693 of 5 stars
$224.46
+0.1%
$243.82
+8.6%
+13.4%$32.97B$4.93B26.508,160Analyst Forecast
Positive News
DXCM
DexCom
4.8788 of 5 stars
$71.35
+0.9%
$99.82
+39.9%
-44.7%$27.88B$4.03B49.907,600
STE
STERIS
4.5107 of 5 stars
$227.84
+0.5%
$258.75
+13.6%
-3.0%$22.39B$5.40B48.3718,179News Coverage
Positive News
BAX
Baxter International
4.1552 of 5 stars
$34.85
+0.7%
$38.56
+10.6%
-20.9%$17.83B$10.64B-27.2260,000Short Interest ↑
HOLX
Hologic
4.9397 of 5 stars
$61.82
+1.8%
$84.62
+36.9%
-18.6%$13.87B$4.04B19.507,063Analyst Revision
News Coverage
Positive News
GMED
Globus Medical
4.8178 of 5 stars
$72.16
+1.6%
$97.82
+35.5%
+41.3%$9.93B$2.52B96.225,000Analyst Forecast
MASI
Masimo
3.7621 of 5 stars
$172.78
+2.7%
$194.80
+12.7%
+24.6%$9.32B$2.09B119.166,200Analyst Revision
Positive News
Remove Ads

Related Companies and Tools


This page (NASDAQ:PODD) was last updated on 3/22/2025 by MarketBeat.com Staff
From Our Partners